Prasad V Chaturvedula

This inventor holds 31 USPTO granted patents and 2 published patent applications, plus 2 CIPO patents and 5 EPO patents, primarily in CGRP Antagonists. Top assignees: Bristol-Myers Squibb Compnay, Sanofi, Vertex Pharmaceuticals, Inc.. Active years: 1996-2013.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Prasad V Chaturvedula. Retrieved from https://idiyas.com/inventor/prasad-v-chaturvedula

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 31 (Patent Applications = 2)

% Patents Active = 96.8

CIPO Patents = 2 (Patent Applications = 2)

EPO Patents = 5 (Patent Applications = 3)

Average Co-Inventor Count = 3.8

ph-index = 11

Forward Citations = 1,297(Granted Patents)

Location History:

Exton, PA (US) (1996 - 1999)
Cheshiye, CT (US) (1999)
Cheshire, CT (US) (1996 - 2013)

Company Filing History:

17 out of 3,742

Bristol-Myers Squibb Compnay

Vertex Pharmaceuticals, Inc.

patents

4. 1 out of 41

Bristol Meyers Squibb Company

Sterling Winthrop Inc.

patents

where one patent can have more than one assignee

Years Active: 1996-2013

Loading Chart...

Areas of Expertise:

CGRP Antagonists

Anti-Migraine Treatments

Interleukin-1 Inhibitors

Spirocyclic Compounds

Heterocyclic Agents

Peptide Analogs

Nucleosides

Benzodiazepinone

Calcitonin Gene Related Peptide

Amidoheterocycles

Oligonucleotide Analogues

Fused-Bicyclic Lactams

31 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 8592423 - Inhibitors of PDE10 (2013-11-26),

2. 8481546 - CGRP receptor antagonist (2013-07-09),

3. 7842808 - Anti-migraine spirocycles (2010-11-30),

4. 7834007 - CGRP antagonists (2010-11-16),

5. 7754732 - Spirocyclic anti-migraine compounds (2010-07-13),

6. 7569578 - Heterocyclic anti-migraine agents (2009-08-04),

7. 7544680 - Constrained compounds as CGRP-receptor antagonists (2009-06-09),

8. 7470680 - Constrained compounds as CGRP-receptor antagonists (2008-12-30),

9. 7470679 - Constrained compounds as CGRP-receptor antagonists (2008-12-30),

10. 7449586 - Processes for the preparation of CGRP-receptor antagonists and intermediates thereof (2008-11-11),

11. 7384931 - Constrained compounds as CGRP-receptor antagonists (2008-06-10),

12. 7384930 - Constrained compounds as CGRP-receptor antagonists (2008-06-10),

13. 7314883 - Anti-migraine treatments (2008-01-01),

14. 7220862 - Calcitonin gene related peptide receptor antagonists (2007-05-22),

15. 7049323 - Amidoheterocycles as modulators of the melanocortin-4 receptor (2006-05-23),

Title: Innovations by Prasad V Chaturvedula: A Leading Inventor in Pharmaceutical Advancements

Introduction

Prasad V Chaturvedula is a prominent inventor located in Cheshire, CT, USA. With an impressive count of 31 patents to his name, he has significantly contributed to the pharmaceutical field. His inventions focus on developing compounds for various medical applications, including treatments for migraines and other complex disorders.

Latest Patents

Among his latest patents are innovative inhibitors of PDE10 and a novel CGRP receptor antagonist. The PDE10 inhibitors are characterized by a specific general formula, paving the way for advanced compositions and methods aimed at inhibiting PDE10. Additionally, his work on the CGRP receptor antagonist involves a detailed compound formula, which is notable for its potential in treating CGRP-related disorders. These disorders encompass migraine headaches, neurogenic vasodilation, and various airway inflammatory diseases like asthma and chronic obstructive pulmonary disease (COPD).

Career Highlights

Chaturvedula's career includes significant roles at renowned companies such as Bristol-Myers Squibb Company and Sanofi. Through his tenure at these organizations, he has been pivotal in advancing pharmaceutical research and development initiatives, contributing to numerous projects that have heightened the efficacy of medical treatments.

Collaborations

Throughout his career, Chaturvedula has collaborated with notable colleagues, including Roland Ellwood Dolle and Stanley J Schmidt. These collaborations have fostered a vibrant environment of innovation, driving forward key projects that enhance therapeutic options available in the market.

Conclusion

Prasad V Chaturvedula's contributions as an inventor continue to resonate within the pharmaceutical industry. With a robust patent portfolio and a commitment to collaborative innovation, he stands as a beacon of advancement in medical science, and his work promises to impact the future of drug development significantly.

Profile summary based on public USPTO records.